Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | BAD | Q92934 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | EDNRB | P24530 | 2/20 | 0.32 |
| ▸ | EDNRA | P25101 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | PREP | P48147 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128658 | 0.86 | TARBP2 (0.37) | TARBP2PTGS1PTGS2CYP3A4MAPT | |
| SCHEMBL128821 | 0.81 | CYP3A4 (0.39) | TARBP2CYP3A4MAPTACHEBCHE | |
| SCHEMBL129768 | 0.77 | PTGS1 (0.44) | PTGS1PTGS2CYP3A4MAPTACHE | |
| SCHEMBL129785 | 0.77 | ACHE (0.43) | CYP3A4MAPTACHEBCHEPREP | |
| SCHEMBL127656 | 0.74 | ACHE (0.38) | BADCYP3A4MAPTACHEBCHE | |
| SCHEMBL128826 | 0.74 | BAD (0.36) | TARBP2BADCYP3A4MAPTACHE | |
| SCHEMBL129789 | 0.68 | CYP1B1 (0.47) | CYP3A4MAPTACHEBCHEPREP | |
| SCHEMBL129791 | 0.67 | ACHE (0.41) | CYP3A4MAPTACHEBCHEPREP | |
| SCHEMBL128827 | 0.67 | CYP1B1 (0.40) | PTGS1PTGS2CYP3A4MAPTACHE | |
| SCHEMBL16189647 | 0.66 | BCHE (0.52) | BADCYP3A4MAPTACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227966-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | TARBP2 3402/4885PTGS1 2524/4885PTGS2 2553/4885 |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | TARBP2 3466/4885PTGS1 2892/4885PTGS2 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.